Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

But making AbbVie an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV ...

Breast Reconstruction Market Outlook to 2031The global breast reconstruction market was valued at US$ 1.4 billion in 2021 and is projected to grow at a CAGR of 5.3% from 2022 to 2031, reaching more ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of. Ms. Kalofonos will lead the company’s commercial strategy and operations for the potential launch of paltusotine, the ...

Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, AbbVie, and Biogen ... Merck & Company (MRK) Company Description: Merck & Co., Inc. develops pharmaceutical and vaccine ...

AbbVie is a strong investment opportunity with growth potential, dividend income, and a diverse drug portfolio. Find out why ...

In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.

AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics.

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...